Ronit Katz

Supplementary Figure S5 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications

Kalyan Banda, Helen Ruth Davies, Yogesh Kumar, Yasin Memari et autres

Supplementary Figure 5: Comparative genomic characteristics of HRDetect-intermediate and low groups.

Supplementary Figure S2 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications

Kalyan Banda, Helen Ruth Davies, Yogesh Kumar, Yasin Memari et autres

Supplementary Figure 2: CONSORT diagram of the ARIEL 2 PART 1 clinical trial cohort.

Supplementary Figure S1 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications

Kalyan Banda, Helen Ruth Davies, Yogesh Kumar, Yasin Memari et autres

Supplementary Figure 1: CONSORT diagram of the UW ovarian cancer cohort

Supplementary Figure S6 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications

Kalyan Banda, Helen Ruth Davies, Yogesh Kumar, Yasin Memari et autres

Supplementary Figure 6: Copy number signatures in UW cohort.

Supplementary Figure S3 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications

Kalyan Banda, Helen Ruth Davies, Yogesh Kumar, Yasin Memari et autres

Supplementary Figure 3: Additional genomic characteristics in HRDetect groups.

Supplementary Figure S4 from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications

Kalyan Banda, Helen Ruth Davies, Yogesh Kumar, Yasin Memari et autres

Supplementary Figure 4: Comparative genomic characteristics of HRDetect-intermediate versus high groups

Data from HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications

Kalyan Banda, Helen Ruth Davies, Yogesh Kumar, Yasin Memari et autres

Abstract Purpose: To evaluate HRDetect, a mutational signature–based algorithm, for prognostic utility in tubo-ovarian carcinoma and to determine if whole-genome sequencing (WGS) with rearrangement signature (RS) analysis can refine genomic classification beyond the traditional homologous recombination–deficient versus homologous recombination–proficient framework. Experimental Design: …

Kidney Tubular Secretion Capacity and Risk of Cardiovascular Mortality in the General Population

Alexander L. Bullen, Ronit Katz, Simon B. Ascher, Pranav Sandilya Garimella et autres

BACKGROUND: Kidney tubular secretion is a critical mechanism for the clearance of numerous metabolites, toxins, and drugs. In populations with advanced chronic kidney disease (CKD), low (worse) tubular secretion has been associated with an increased risk of cardiovascular disease (CVD). However, it …

us, no (code pays fourni par la source)

HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications.

Kalyan Banda, Helen Ruth Davies, Yogesh Kumar, Yasin Memari et autres

PURPOSE: To evaluate HRDetect, a mutational signature-based algorithm, for prognostic utility in tubo-ovarian carcinoma and to determine if whole-genome sequencing (WGS) with rearrangement signature (RS) analysis can refine genomic classification beyond the traditional homologous recombination-deficient versus homologous recombination-proficient framework. EXPERIMENTAL DESIGN: WGS …

Streamlining intrapartum glycemic control: Subcutaneous insulin for intrapartum diabetes management

Leah M. Savitsky, Chantelle Barr, Ronit Katz, Nadine Martinez et autres

Abstract Objective Optimal strategies for intrapartum glycemic control among patients with gestational diabetes mellitus (GDM) and type 2 diabetes mellitus (T2DM) remain uncertain. In 2024, our labor and delivery unit implemented a subcutaneous (SC) insulin protocol to replace routine intravenous (IV) insulin …

us (code pays fourni par la source)

Association of Proximal Tubule Secretion With Hyperkalemia Risk, Treatment Response, and Outcomes in Heart Failure With Preserved Ejection Fraction

Nicholas Wettersten, Ronit Katz, Pranav S. Garimella, Alexander L. Bullen et autres

Rationale & Objective: Endogenous biomarkers reflecting impaired kidney tubular secretion are associated with risk of hyperkalemia in patients with hypertension and chronic kidney disease. Whether these biomarkers are associated with risk of hyperkalemia, therapeutic response, and adverse cardiovascular and kidney events in …

us, jp (code pays fourni par la source)

Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals

Brendon Neuen, Rupert W. Major, Morgan E. Grams, Yingying Sang et autres

The American Heart Association's PREVENT equations estimate risk of total cardiovascular disease (CVD), atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) to guide lipid-lowering and blood pressure-lowering therapy in people ages 30-79 years in the United States. The SCORE2 risk algorithm is …

au, gb, us, fr, se, de, es, nl, at, br, ca, jp, sg (code pays fourni par la source)